b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="jonc" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2864512/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864512/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Journal of Oncology" /><meta name="citation_title" content="Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy" /><meta name="citation_authors" content="Han-Chung Wu, De-Kuan Chang" /><meta name="citation_date" content="2010" /><meta name="citation_volume" content="2010" /><meta name="citation_doi" content="10.1155/2010/723798" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2864512/?report=abstract" /><meta name="citation_pmid" content="20454584" /><meta name="DC.Title" content="Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Hindawi Limited" /><meta name="DC.Contributor" content="Han-Chung Wu" /><meta name="DC.Contributor" content="De-Kuan Chang" /><meta name="DC.Date" content="2010" /><meta name="DC.Identifier" content="10.1155/2010/723798" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy" /><meta property="og:type" content="article" /><meta property="og:description" content="Solid tumors are known to recruit new blood vessels to support their growth. Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer. Current efforts are focusing on developing ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864512/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-jonc.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2864512/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2864512/pdf/JO2010-723798.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B572CE9A363910000000008DF08DD.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/859/">J Oncol</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/180269/">v.2010; 2010</a></li><li class="accid">PMC2864512</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-jonc.png" alt="Logo of jonc" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,500,75" alt="Journal of Oncology" title="Journal of Oncology" href="http://www.hindawi.com/journals/jo/" ref="reftype=publisher&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">J Oncol</span>. 2010; 2010: 723798. </span></div><div><span class="fm-vol-iss-date">Published online 2010 May 5. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1155%2F2010%2F723798" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1155/2010/723798</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2864512</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20454584">20454584</a></div></div></div></div><h1 class="content-title">Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Wu%20HC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20454584" class="affpopup" co-rid="_co_idm139821373366816" co-class="co-affbox">Han-Chung Wu</a><sup>\n</sup><sup>*</sup> and  <a href="/pubmed/?term=Chang%20DK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20454584" class="affpopup" co-rid="_co_idm139821373364960" co-class="co-affbox">De-Kuan Chang</a><sup>\n</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139821373366816"><h3 class="no_margin">Han-Chung Wu</h3><p>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan</p><div>Find articles by <a href="/pubmed/?term=Wu%20HC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20454584">Han-Chung Wu</a></div></div><div id="_co_idm139821373364960"><h3 class="no_margin">De-Kuan Chang</h3><p>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan</p><div>Find articles by <a href="/pubmed/?term=Chang%20DK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20454584">De-Kuan Chang</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139821376657760_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139821376657760_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139821376657760_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139821376657760_ai" style="display:none"><div class="fm-affl" lang="en" id="I1">Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan</div><div id="cor1">*Han-Chung Wu: <a href="mailto:dev@null" data-email="wt.ude.acinis.etag@8290wch" class="oemail">wt.ude.acinis.etag@8290wch</a></div><div id="idm139821367646240">Academic Editor: Arkadiusz Dudek</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139821376657760_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2009 Nov 3; Revised 2010 Jan 13; Accepted 2010 Mar 3.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139821376657760_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2010 H.-C. Wu and D.-K. Chang.</div><div class="license half_rhythm">This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2864512/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139821365049680" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139821365049680title">Abstract</h2><!--article-meta--><div><p id="__p2" class="p p-first-last">Solid tumors are known to recruit new blood vessels to support their growth. Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer. Current efforts are focusing on developing therapeutic agents capable of specifically targeting cancer cells and tumor-associated microenvironments including tumor blood vessels. These therapies hold the promise of high efficacy and low toxicity. One recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics is to encapsulate anticancer drugs into targeting liposomes that bind to the cell surface receptors expressed on tumor-associated endothelial cells. These anti-angiogenic drug delivery systems could be used to target both tumor blood vessels as well as the tumor cells, themselves. This article reviews the mechanisms and advantages of various present and potential methods using peptide-conjugated liposomes to specifically destroy tumor blood vessels in anticancer therapy.</p></div></div><div id="sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1title">1. Introduction</h2><p id="__p3" class="p p-first">One of the primary goals of a successful cancer treatment regimen is to deliver sufficient amounts of drug to tumors while minimizing damage to normal tissues. Most chemotherapeutic agents enter normal tissues in the body with indiscriminate cytotoxicity and do not preferentially accumulate at tumor sites. At times the dose reaching the tumor may be as little as 5% to 10% of the doses accumulating in normal organs [<a href="#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473672">1</a>, <a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473581">2</a>]. One reason for the inability for drugs to accumulate at target sites is that the interstitial fluid pressure (IFP) in solid tumors is higher than in normal tissues, that blocking transcapillary transport of chemotherapeutic drugs or antibodies [<a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473578">3</a>&#x02013;<a href="#B5" rid="B5" class=" bibr popnode">5</a>]. In this way, the anticancer effect is decreased and toxic effect to normal cells is increased. Fear of severely harming the patients often limits the dose of anticancer drugs that can be given to a patient. These lower than optimal doses elicit incomplete tumor responses which leads to disease relapse and drug resistance. Therefore, most cancer drugs fail in clinical studies not because they are ineffective in killing cancer cells but because they cannot be administered in doses high enough to eradicate the tumor without severely harming the patient. </p><p id="__p4" class="p p-last">Several approaches have been developed to improve the ability of anticancer drug to more specifically target tumors and avoid normal organs. One of the most effective strategies is to encapsulate drugs in particles that deliver them preferentially to tumor sites. For example, liposome particles have been found able to deliver radionuclides, genes, and chemotherapeutic agents to tumor sites. [<a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473582">6</a>&#x02013;<a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473584">10</a>]. Another promising strategy is to encapsulate anticancer drugs in liposomes conjugated with moieties, such as antibodies and peptides, that target particular types of target tumor cells or tumor vasculatures [<a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473580">11</a>&#x02013;<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473607">13</a>]. Use of internalizing ligands for targeting liposomes conjugated with such moieties makes it possible to deliver the chemotherapeutic drugs encapsulated within them to the cytosol through the receptor-mediated endocytosis [<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473678">14</a>&#x02013;<a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473622">17</a>]. This article reviews the current research in developing liposomal drug delivery systems that use peptide ligands to target blood vessels in solid tumors. We discuss the identification of peptides that can target tumor blood vessels and the use of targeting and nontargeting liposomes to encapsulate and deliver chemotherapeutic drugs to tumor sites.</p></div><div id="sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2title">2. Inhibiting Angiogenesis</h2><p id="__p5" class="p p-first">Virtually every conventional cytotoxic drug has been found to be antiangiogenic in in vitro and in vivo models [<a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473623">18</a>]. One treatment approach known as metronomic therapy uses frequent administrations of low-dose antiangiogenic agents to destroy vessels in tumors while decreasing the toxicity to normal tissues [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473637">19</a>&#x02013;<a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473671">21</a>]. For example, it has been found in mice that frequent administration of relatively low, noncytotoxic doses of liposome-encapsulated doxorubicin can shrink various solid tumor xenografts [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473572">13</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473681">16</a>]. The antiangiogenic agent bevacizumab (Avastin), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been used with some success to treat advanced colon cancer. One study compared the effect using three chemotherapeutic agents alone to treat advanced colon cancer with using the three agents combined with bevacizumab [<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473684">22</a>]. They found that the combined use of chemotherapeutic agents and bevacizumab extended overall survival by approximately 4.7 months compared to the use of chemotherapeutic agents alone [<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473673">22</a>]. Other angiogenesis inhibitors, including sunitinib and sorafenib, have also been found to improve clinical outcomes when used to treat various cancer types [<a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473564">23</a>, <a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473618">24</a>].</p><p id="__p6">The targeting of proliferating endothelial cells in the blood vessels of tumors has several advantages. First, endothelial cells in malignant tumors are genetically stable, nonmalignant, and rarely drug resistant, compared to the cancer cells [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473658">19</a>, <a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473596">21</a>]. However, some recent studies show that tumor-associated endothelial cells can acquire cytogenetic abnormalities while they are in the tumor microenvironment [<a href="#B84" rid="B84" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473625">25</a>, <a href="#B85" rid="B85" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473609">26</a>]. Second, the destruction of endothelial cells using this method amplifies the drugs antitumor effect. It has been reported that the elimination of one endothelial cell can inhibit the growth of as many as a hundred tumor cells [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473560">27</a>, <a href="#B26" rid="B26" class=" bibr popnode">28</a>]. Third, antiangiogenic therapy decreases IFP within the tumor allowing better penetration by chemotherapeutic agents [<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473677">29</a>&#x02013;<a href="#B30" rid="B30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473606">32</a>]. For example, Jain found that bevacizumab could decrease IFP by normalizing tumor vasculature and decreasing vascular leakage [<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473620">29</a>, <a href="#B31" rid="B31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473649">33</a>]. Fourth, antiangiogenic therapy is known to inhibit the growth of both primary and metastatic solid tumors. Finally, intravenously injected angiogenesis inhibitors can directly reach endothelial cells.</p><p id="__p7" class="p p-last">In addition, we can take advantage of the differences between endothelial cell plasma membrane proteins (i.e., vascular zip codes) to develop drug delivery systems capable of guiding therapeutic or imaging agents to a particular organ or tumor [<a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473603">34</a>, <a href="#B33" rid="B33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473665">35</a>]. Endothelial cells of blood vessels within solid tumors express certain molecular structures that are absent or minimally detectable in normal blood vessels [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473652">13</a>, <a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473647">36</a>, <a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473629">37</a>]. These structures can be used as molecular targets for antitumor treatment. </p></div><div id="sec3" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3title">3. Identifying Peptides That Target Tumor Blood Vessels</h2><p id="__p8" class="p p-first">The key to delivering drugs specifically to these targets is to identify and use ligands that specifically bind to and that can be internalized by endothelial cells in tumors. Combinatorial peptide libraries displayed on microorganisms have become a research tool for identifying cell surface-binding peptides that can become targets for antitumor treatment. Of the many molecular display techniques, phage display has been the most popular approach. Phage display is a selection technique in which a peptide or protein is fused with a coat protein of bacteriophage and displayed on the surface of the virion. Phage-displayed random peptide libraries have helped researchers map B-cell epitopes [<a href="#B36" rid="B36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473653">38</a>&#x02013;<a href="#B38" rid="B38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473566">40</a>], discover protein-protein contacts [<a href="#B39" rid="B39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473601">41</a>, <a href="#B40" rid="B40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473627">42</a>], and identify bioactive peptides bound to receptors [<a href="#B41" rid="B41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473585">43</a>, <a href="#B42" rid="B42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473668">44</a>] or proteins [<a href="#B43" rid="B43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473624">45</a>, <a href="#B44" rid="B44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473656">46</a>]. Peptide libraries can be used to find disease-specific antigens [<a href="#B45" rid="B45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473628">47</a>, <a href="#B46" rid="B46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473574">48</a>] and cell- [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473586">2</a>, <a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473676">49</a>] and organ-specific peptides [<a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473561">16</a>, <a href="#B33" rid="B33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473636">35</a>, <a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473639">36</a>]. </p><p id="__p9" class="p p-last">Recently, using affinity selection (biopanning) of phage-displayed peptide libraries, researchers have discovered molecules that are expressed on tumor blood vessels exclusively [<a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473568">16</a>, <a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473567">34</a>&#x02013;<a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473576">36</a>]. The strategy for identifying tumor-targeting ligands and developing ligand-mediated targeted therapy is shown in <a href="/pmc/articles/PMC2864512/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span>Figure 1</span></a>. Researchers have used in vivo affinity selection of phage libraries to identify peptides that interact with the molecules found on endothelia in tumors [<a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473621">34</a>, <a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473657">36</a>]. The NGR peptide motif targets angiogenic blood vessels [<a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473608">36</a>] and the tumor-homing property of NGR motif relies on recognition of a CD13 isoform selectively expressed within tumor blood vessels [<a href="#B83" rid="B83" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473680">54</a>]. Compared with the nontargeting liposomal doxorubicin (Caelyx), NGR peptide-conjugated Caelyx significant improvements in survival was seen in clinically relevant animal models of neuroblastoma, ovarian, and lung cancers [<a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473600">17</a>]. Another peptide, SP5-52, has been found to recognize blood vessels created in tumors but not normal blood vessels in severe combined immunodeficiency (SCID) mice bearing solid tumors. Several selected phage clones display Pro-Ser-Pro, a motif crucial to peptide binding to tumor neovasculature [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473663">13</a>]. Several tumor homing peptides have been found to bind to blood vessels in surgical specimens of human cancer and they have also been found to home to tumor tissues of different human tumor xenografts as confirmed by in vivo homing assays [<a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473635">16</a>]. These studies found a greater correlation between increased tumoral accumulation of the targeting liposomes and antitumor efficacy than the accumulation of free drugs or drugs formulated in the nontargeting liposomes [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473588">2</a>, <a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473664">13</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473595">16</a>].</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig1" co-legend-rid="lgnd_fig1"><a href="/pmc/articles/PMC2864512/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139821376731744" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2864512_JO2010-723798.001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is JO2010-723798.001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2864512/bin/JO2010-723798.001.jpg" /></a></div><div id="largeobj_idm139821376731744" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2864512/figure/fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig1"><div><a class="figpopup" href="/pmc/articles/PMC2864512/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p22">Selection of peptides that target tumor blood vessels using in vivo phage display. Peptide or antibody libraries are expressed as fusion proteins with a coat protein (pIII) of a bacteriophage, and the fused proteins are displayed on the surface of the virion. A phage-displayed peptide library was injected through the tail vein of tumor-bearing mice. Eight minutes after injection, the mice were perfused through the heart. Phage recovered from the tumor was amplified and reinjected in mice for another four rounds. Tumor-targeting phages were further identified by in vivo tumor-homing assay, synthetic peptide binding and competition assay, and immunohistochemical staining. The identified peptides can be used as ligands to recognize cell surface markers or tumor antigens to develop targeted therapy. SCID mice bearing human cancer xenografts were successfully treated with ligand-conjugated antiangiogenic targeting liposomes.</p></div></div></div></div><div id="sec4" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4title">4. Drug-Encapsulated Liposomes</h2><p id="__p10" class="p p-first">Most of the drug delivery systems approved for marketing are liposomal- or lipid-based formulations or therapeutic molecules linked to polyethylene glycol (PEG) [<a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473589">6</a>, <a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473605">10</a>, <a href="#B48" rid="B48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473616">55</a>, <a href="#B49" rid="B49" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473645">56</a>]. One such product is PEGylated liposomal doxorubicin, which is known as Doxil in the US and Caelyx in Europe [<a href="#B50" rid="B50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473640">57</a>]. It is currently approved for the treatment of AIDS-related Kaposi\'s sarcoma and recurrent ovarian cancer in North America, Europe, and other countries, and for metastatic breast cancer in Europe. Liposome-encapsulated doxorubicin has been found to significantly improve the therapeutic index of doxorubicin both in preclinical [<a href="#B51" rid="B51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473592">58</a>&#x02013;<a href="#B53" rid="B53" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473655">60</a>] and in clinical studies [<a href="#B54" rid="B54" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473577">61</a>&#x02013;<a href="#B57" rid="B57" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473643">64</a>]. An important advantage of PEGylated liposomal doxorubicin is that the heart muscle uptakes much less of it than free doxorubicin [<a href="#B51" rid="B51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473631">58</a>, <a href="#B58" rid="B58" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473599">65</a>]. One study found no cardiotoxicity in 40 patients receiving cumulative doses of 500&#x02013;1500&#x02009;mg/m<sup>2</sup> of doxorubicin [<a href="#B55" rid="B55" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473667">62</a>]. Free doxorubicin, on the other hand, is limited to a maximum recommended cumulative dose of 450&#x02013;550&#x02009;mg/m<sup>2</sup>. Colbern et al. found that the activity of PEGylated liposomal doxorubicin 1-2&#x02009;mg/kg was almost equivalent to that of free doxorubicin 9&#x02009;mg/kg in mouse Lewis lung carcinoma [<a href="#B52" rid="B52" class=" bibr popnode">59</a>]. One clinical study reported that most (&#x0003e;98%) of the drug circulating in the blood stream remains in encapsulated in liposomes [<a href="#B54" rid="B54" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473570">61</a>], suggesting that little of the liposomal drugs will be leaked to the circulation system during its journey to the tumor tissues.</p><p id="__p11">The hyperpermeability of tumor vasculature is a key factor for the success of liposome-delivered chemotherapy agents. The &#x0201c;leakiness&#x0201d; of the angiogenic tumor vasculature is estimated to have an average pore size of 100&#x02013;600&#x02009;nm [<a href="#B70" rid="B70" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473619">66</a>]. These pores are significantly larger than the gap junction found in normal endothelium, which are typically &#x0003c;6&#x02009;nm wide [<a href="#B71" rid="B71" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473651">67</a>]. Liposomes with diameters of approximately 65&#x02013;75&#x02009;nm [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473612">13</a>, <a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473615">14</a>, <a href="#B66" rid="B66" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473666">50</a>] are small enough to passively infiltrate tumor endothelium but large enough to be excluded from normal endothelium. Hence, they selectively extravasate into the tumor interstitial space. In the tissue of solid tumors, vasculature becomes so permeable that particulate liposomes can extravasate and localize in the tissue interstitial space [<a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473641">6</a>, <a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473632">10</a>]. In addition, tumor tissues frequently lack effective lymphatic drainage [<a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473654">3</a>], which means that the liposomes can be retained longer. Together, these factors increase the accumulation of the drug within the tumor, which has been referred to as the &#x0201c;enhanced permeability and retention (EPR) effect&#x0201d; by Maeda et al. [<a href="#B72" rid="B72" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473613">68</a>, <a href="#B73" rid="B73" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473675">69</a>]. EPR-mediated passive tumor targeting by liposomes can increase the concentration of drugs in solid tumors by as much as ten times, compared to free drugs [<a href="#B74" rid="B74" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473660">70</a>]. </p><p id="__p12" class="p p-last">Passively targeted liposomal drug delivery systems have some disadvantages. Normal organ uptake of liposomes leads to accumulation of the encapsulated drug in mononuclear phagocytic system cells in the liver, spleen, and bone marrow [<a href="#B56" rid="B56" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473683">63</a>], which may present hazards to these tissues. For example, with increased circulation time of these drugs may come increased toxicity inducing such problems as hand-foot syndrome, mucositis, and hematological toxicities such as neutropenia, thrombocytopenia, and leucopenia [<a href="#B59" rid="B59" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473626">71</a>&#x02013;<a href="#B62" rid="B62" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473642">74</a>]. Therefore, ongoing research aims at enhancing the tumor site-specific action of the liposomes by attaching ligands to surface molecules of tumor cells and tumor vasculature, a process called active or ligand-mediated targeting liposomes [<a href="#B5" rid="B5" class=" bibr popnode">5</a>, <a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473573">6</a>, <a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473602">13</a>, <a href="#B63" rid="B63" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473591">75</a>].</p></div><div id="sec5" class="tsec sec"><h2 class="head no_bottom_margin" id="sec5title">5. Peptide-Mediated Targeting Liposomes</h2><p id="__p13" class="p p-first">The disadvantage of the passive PEGylated liposomes can be overcome by creating ligand-mediated targeting liposomes with more selective anticancer activity. The activity of anticancer drugs can be enhanced by coupling targeting moieties to the surface of liposomes to promote selective binding to tumor-associated antigens and facilitate the delivery of drug-containing liposomes to the intended cellular sites. This drug delivery system has a higher drug-to-carrier ratio than immunoconjugates and multivalent presentation of ligands, which increases their binding avidity [<a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473670">11</a>]. </p><p id="__p14">Antibodies that bind to tumor-specific antigens have so far yielded little success as a drug delivery system for solid tumors, which make up more than 90% of all cancers in humans. Although monoclonal antibodies have shown clinical potential as tumor targeting agents, they are limited by their large molecular size and poor tumor penetration [<a href="#B64" rid="B64" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473644">76</a>], by the immunogenicity associated with immunoliposomes, and by their toxicity to liver and bone marrow from nonspecific antibody uptake. These limitations can be overcome by using peptide ligands, which are smaller, less immunogenic molecules, and easier to produce and manipulate. Furthermore, peptide ligands have moderate affinity to antigens, which is beneficial because extremely high affinity of antibody-binding can impair tumor penetration [<a href="#B65" rid="B65" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473634">77</a>]. Compared with antibody ligands, peptide ligands can improve tumor penetration and decrease MPS clearance of conjugated liposomes [<a href="#B66" rid="B66" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473638">50</a>, <a href="#B67" rid="B67" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473648">78</a>]. The increasing use of peptides as targeting ligands has been aided by the use of phage display to identify novel ligands (<a href="/pmc/articles/PMC2864512/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span>Figure 1</span></a>). Researchers have already produced liposomes conjugated with ligands that specifically target tumor cells or tumor vasculature [<a href="#B5" rid="B5" class=" bibr popnode">5</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473614">16</a>, <a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473617">17</a>].</p><p id="__p15">Peptide-conjugated liposomes have three main components: anticancer drug, a liposome carrier, and targeting peptide (<a href="/pmc/articles/PMC2864512/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span>Figure 2</span></a>). Remote loading methods such as the ammonium sulfate method [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473593">13</a>, <a href="#B68" rid="B68" class=" bibr popnode">79</a>] and the pH gradient method [<a href="#B69" rid="B69" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473611">80</a>] can encapsulate weak bases such as doxorubicin or vinorelbine into the liposomes with more than 95% efficiency. Schedule-dependent drugs such as vinca alkaloids, topotecan, and 5-fluorouracil are also potential candidates for liposomal delivery because they can extend the time when cancer cells are exposed to therapeutic levels of the drug. </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig2" co-legend-rid="lgnd_fig2"><a href="/pmc/articles/PMC2864512/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139821368981360" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2864512_JO2010-723798.002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is JO2010-723798.002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2864512/bin/JO2010-723798.002.jpg" /></a></div><div id="largeobj_idm139821368981360" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2864512/figure/fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig2"><div><a class="figpopup" href="/pmc/articles/PMC2864512/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p23">Generation of peptide-conjugated liposomes targeting tumor blood vessels. A single lipid bilayer membrane separates an internal aqueous compartment from the external medium. Doxorubicin was encapsulated in the internal compartment. Drug molecules are tightly packed (10,000 to 15,000 molecules per liposome) in a gel phase. Tumor-homing peptide ligands were coupled to NHS-PEG-DSPE [N-hydroxysuccinimido-carboxyl-polyethylene glycol-derived distearoylphosphatidylethanolamine] in a 1&#x02009;:&#x02009;1.5 molar ratio [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473662">13</a>, <a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473661">14</a>, <a href="#B66" rid="B66" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473682">50</a>]. The reaction was completed and confirmed by quantifying the remaining amino groups using TNBS (Trinitrobenzenesulfonate) reagent [<a href="#B80" rid="B80" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473633">51</a>]. Peptidyl-PEG-DSPE was transferred to preformed liposomes after coincubation at a temperature above the transition temperature of the lipid bilayer [<a href="#B81" rid="B81" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473563">52</a>]. There were 500 peptide molecules per liposome [<a href="#B82" rid="B82" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473650">53</a>]. The mean diameter of the targeting liposome is approximately 75&#x02009;nm [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473571">2</a>, <a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473610">13</a>].</p></div></div></div><p id="__p16">The bioavailability and pharmacodynamics of liposome-encapsulated chemotherapeutic drugs must be considered in developing these delivery systems. To take advantage of the EPR effect, liposomes need to have long half-lives so that the drug stays within the carrier as long as possible in blood circulation until it accumulates in diseased tissues [<a href="#B75" rid="B75" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473598">81</a>]. Once liposomes are localized to a solid tumor, the drug they contain must be released and become bioavailable at a rate remains therapeutically effective for a period of time. The rate of active drug\'s release into tumor cells, not the total drug concentration in the tumor tissues, is critical for measuring the actual bioavailability of the liposomal drug [<a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473597">16</a>]. Some targeting liposomes have not been found to have greater therapeutic efficacy than passive liposomal drugs, possibly because the lack of internalizing ligands does not give the drug greater access inside tumor cells [<a href="#B76" rid="B76" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473565">82</a>, <a href="#B77" rid="B77" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473630">83</a>]. Drug delivery can be further enhanced if the liposome-attached ligands bind selectively to internalizing antigens which would help increase the concentration of drugs inside tumor or tumor-associated endothelial cells resulting in higher drug concentration inside the cells [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473646">13</a>, <a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473569">15</a>, <a href="#B78" rid="B78" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473659">84</a>, <a href="#B79" rid="B79" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473562">85</a>]. This binding to internalizing antigens by ligands can induce receptor-mediated endocytosis of liposomes into endosome compartments with low pH, where the liposomes break down and release the encapsulated drug into the intracellular space (<a href="/pmc/articles/PMC2864512/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure 3</span></a>). These steps lead to higher intracellular drug concentration and greater destruction or inhibition of tumor cells. Studies have confirmed greater cytotoxic effects produced by liposomes with peptides that target internalizing antigens through enhanced specificity and improved drug bioavailability [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473685">2</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473583">16</a>]. </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="fig3" co-legend-rid="lgnd_fig3"><a href="/pmc/articles/PMC2864512/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139821371059904" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2864512_JO2010-723798.003.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is JO2010-723798.003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2864512/bin/JO2010-723798.003.jpg" /></a></div><div id="largeobj_idm139821371059904" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2864512/figure/fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig3"><div><a class="figpopup" href="/pmc/articles/PMC2864512/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p24">Diagram of the molecular mechanism of peptide-conjugated liposomes on cancer therapy. These liposomes prolong circulation time in blood and improve pharmacokinetic and biodistribution of their encapsulated drugs. After intravenous administration, liposomes are large enough to be excluded from normal endothelium. In solid tumors, the angiogenic tumor vasculature becomes leakiness that particulate liposomes can extravasate and localize in the tissue interstitial space making it possible for more drug delivering liposomes to accumulate within the tumor by EPR effect. Coupling liposomes with peptides targeted to tumor cells or tumor vasculature further enhances the specificity and accumulation of liposomes in the tumor. On arrival in the tumor tissues, the liposomes are bound and internalized by tumor cells or tumor-associated endothelial cells through receptor-mediated endocytosis, fused with the low pH compartments of the endosomes, and subsequently broken down the liposomes and to release encapsulated drugs into the intracellular space of the cells.</p></div></div></div><p id="__p17">The use of drug-encapsulated liposomes with ligands to target tumor blood vessels allows us to destroy both tumor blood vessels and tumor cells. In mice bearing human cancer xenograft, low dose of peptide-conjugated liposomal doxorubicin has been found to markedly inhibit vascularization and reduce total volume and weight of tumors [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473579">13</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473674">16</a>, <a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473594">17</a>]. The immunofluorescent analysis of the tumors in several studies has revealed an association between significant decreases in microvessel density and increases in the apoptosis of tumor cells and tumor-associated endothelial cells. The severe damage to tumor vasculature caused by peptide-conjugated liposomal doxorubicin throughout the tumors suggested an improvement in chemotherapeutic efficacy over nontargeting liposomes and conventional drugs [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473679">13</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473587">16</a>, <a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473590">17</a>]. This dual action may produce a greater, more durable anticancer effect than is found with the use of simple antiangiogenic therapy. </p><p id="__p18">One peptide-conjugated liposome can deliver over ten thousand anticancer drug molecules directly into target tumor cells efficiently and effectively. The targeted and sustained release of the drug molecules can increase the maximum tolerated dose (MTD) of the cytotoxic drugs and dramatically lower dose-limiting toxicities, and in turn prevent treatment delay or discontinuation. The affinity of targeting ligands may allow the liposomes to move past the high IFP barrier within tumors [<a href="#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473575">4</a>, <a href="#B5" rid="B5" class=" bibr popnode">5</a>, <a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473669">13</a>, <a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_619473604">16</a>]. </p><p id="__p19" class="p p-last">Advances in nanotechnology and molecular biology are moving us closer to developing an ideal &#x0201c;multifunctional smart nanodrug delivery system&#x0201d; using various types of ligands and drugs based on the kinds of diagnosis, imaging, or therapy needed. Such smart nanodrug delivery systems will allow accurate, specific, and noninvasive disease treatment, early diagnosis, and monitoring. In the future, combining ligands that specifically bind to cancer cells (including cancer stem cells) and tumor blood vessels with multifunctional liposomal drug delivery systems may help improve the effectiveness of cancer treatment and minimize the side effects traditionally associated with chemotherapy.</p></div><div id="sec6" class="tsec sec"><h2 class="head no_bottom_margin" id="sec6title">6. Conclusions</h2><p id="__p20" class="p p-first-last">The development of highly selective anticancer drugs that can discriminate between tumor cells and normal cells is the most important goal of current oncology research. The potential use of ligand-conjugated liposome-encapsulated drugs to target tumor cells and vasculature is very promising. Peptides that specifically bind to tumor targets can be coupled to the PEG terminus of sterically stabilized liposomes and subsequently precisely deliver chemotherapeutic agents to tumor cells or blood vessels. Peptide-mediated liposomes that target vasculature are a new generation of chemotherapy delivery systems with superior pharmacokinetics, controlled biodistribution, efficacy, and safety profiles.</p></div><div id="idm139821371455504" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139821371455504title">Acknowledgment</h2><div class="sec"><p id="__p21">H-C. Wu is supported by the funding from Academia Sinica and National Science Council, Taiwan.</p></div></div><div id="idm139821382073296" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139821382073296title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="element-citation">Bosslet K, Straub R, Blumrich M, et al.  Elucidation of the mechanism enabling tumor selective prodrug monotherapy. <span><span class="ref-journal"><em>Cancer Research</em>. </span>1998;<span class="ref-vol">58</span>(6):1195\xe2\x80\x931201.</span> [<a href="/pubmed/9515805" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Elucidation+of+the+mechanism+enabling+tumor+selective+prodrug+monotherapy&amp;author=K+Bosslet&amp;author=R+Straub&amp;author=M+Blumrich&amp;volume=58&amp;issue=6&amp;publication_year=1998&amp;pages=1195-1201&amp;pmid=9515805&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="element-citation">Chang DEK, Lin CT, Wu CH, Wu HANC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. <span><span class="ref-journal"><em>PLoS ONE</em>. </span>2009;<span class="ref-vol">4</span>(1, article e4171)</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2614347/">PMC free article</a>]</span> [<a href="/pubmed/19137069" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=A+novel+peptide+enhances+therapeutic+efficacy+of+liposomal+anti-cancer+drugs+in+mice+models+of+human+lung+cancer&amp;author=DEK+Chang&amp;author=CT+Lin&amp;author=CH+Wu&amp;author=HANC+Wu&amp;volume=4&amp;issue=1,+article+e4171&amp;publication_year=2009&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="element-citation">Jain RK. Transport of molecules in the tumor interstitium: a review. <span><span class="ref-journal"><em>Cancer Research</em>. </span>1987;<span class="ref-vol">47</span>(12):3039\xe2\x80\x933051.</span> [<a href="/pubmed/3555767" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Transport+of+molecules+in+the+tumor+interstitium:+a+review&amp;author=RK+Jain&amp;volume=47&amp;issue=12&amp;publication_year=1987&amp;pages=3039-3051&amp;pmid=3555767&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="element-citation">Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure&#x02014;an obstacle in cancer therapy. <span><span class="ref-journal"><em>Nature Reviews Cancer</em>. </span>2004;<span class="ref-vol">4</span>(10):806\xe2\x80\x93813.</span> [<a href="/pubmed/15510161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Reviews+Cancer&amp;title=High+interstitial+fluid+pressure&#x02014;an+obstacle+in+cancer+therapy&amp;author=CH+Heldin&amp;author=K+Rubin&amp;author=K+Pietras&amp;author=A+Ostman&amp;volume=4&amp;issue=10&amp;publication_year=2004&amp;pages=806-813&amp;pmid=15510161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="element-citation">Wu HC, Chang DK, Huang CT. Targeted-therapy for cancer. <span><span class="ref-journal"><em>Journal of Cancer Molecules</em>. </span>2006;<span class="ref-vol">2</span>:57\xe2\x80\x9366.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Cancer+Molecules&amp;title=Targeted-therapy+for+cancer&amp;author=HC+Wu&amp;author=DK+Chang&amp;author=CT+Huang&amp;volume=2&amp;publication_year=2006&amp;pages=57-66&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="element-citation">Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. <span><span class="ref-journal"><em>Science</em>. </span>2004;<span class="ref-vol">303</span>(5665):1818\xe2\x80\x931822.</span> [<a href="/pubmed/15031496" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Drug+delivery+systems:+entering+the+mainstream&amp;author=TM+Allen&amp;author=PR+Cullis&amp;volume=303&amp;issue=5665&amp;publication_year=2004&amp;pages=1818-1822&amp;pmid=15031496&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="element-citation">Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KCP. Detection of tumor angiogenesis in vivo by alphaVbeta-targeted magnetic resonance imaging. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>1998;<span class="ref-vol">4</span>(5):623\xe2\x80\x93626.</span> [<a href="/pubmed/9585240" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=Detection+of+tumor+angiogenesis+in+vivo+by+alphaVbeta-targeted+magnetic+resonance+imaging&amp;author=DA+Sipkins&amp;author=DA+Cheresh&amp;author=MR+Kazemi&amp;author=LM+Nevin&amp;author=MD+Bednarski&amp;volume=4&amp;issue=5&amp;publication_year=1998&amp;pages=623-626&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="element-citation">Niethammer AG, Xiang R, Becker JC, et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>2002;<span class="ref-vol">8</span>(12):1369\xe2\x80\x931375.</span> [<a href="/pubmed/12415261" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=A+DNA+vaccine+against+VEGF+receptor+2+prevents+effective+angiogenesis+and+inhibits+tumor+growth&amp;author=AG+Niethammer&amp;author=R+Xiang&amp;author=JC+Becker&amp;volume=8&amp;issue=12&amp;publication_year=2002&amp;pages=1369-1375&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="element-citation">Hood JD, Bednarski M, Frausto R, et al.  Tumor regression by targeted gene delivery to the neovasculature. <span><span class="ref-journal"><em>Science</em>. </span>2002;<span class="ref-vol">296</span>(5577):2404\xe2\x80\x932407.</span> [<a href="/pubmed/12089446" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Tumor+regression+by+targeted+gene+delivery+to+the+neovasculature&amp;author=JD+Hood&amp;author=M+Bednarski&amp;author=R+Frausto&amp;volume=296&amp;issue=5577&amp;publication_year=2002&amp;pages=2404-2407&amp;pmid=12089446&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="element-citation">Cho K, Wang XU, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2008;<span class="ref-vol">14</span>(5):1310\xe2\x80\x931316.</span> [<a href="/pubmed/18316549" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Therapeutic+nanoparticles+for+drug+delivery+in+cancer&amp;author=K+Cho&amp;author=XU+Wang&amp;author=S+Nie&amp;author=Z+Chen&amp;author=DM+Shin&amp;volume=14&amp;issue=5&amp;publication_year=2008&amp;pages=1310-1316&amp;pmid=18316549&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="element-citation">Allen TM. Ligand-targeted therapeutics in anticancer therapy. <span><span class="ref-journal"><em>Nature Reviews Cancer</em>. </span>2002;<span class="ref-vol">2</span>(10):750\xe2\x80\x93763.</span> [<a href="/pubmed/12360278" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Reviews+Cancer&amp;title=Ligand-targeted+therapeutics+in+anticancer+therapy&amp;author=TM+Allen&amp;volume=2&amp;issue=10&amp;publication_year=2002&amp;pages=750-763&amp;pmid=12360278&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="element-citation">Pastorino F, Brignole C, Marimpietri D, et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2003;<span class="ref-vol">63</span>(21):7400\xe2\x80\x937409.</span> [<a href="/pubmed/14612539" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Vascular+damage+and+anti-angiogenic+effects+of+tumor+vessel-targeted+liposomal+chemotherapy&amp;author=F+Pastorino&amp;author=C+Brignole&amp;author=D+Marimpietri&amp;volume=63&amp;issue=21&amp;publication_year=2003&amp;pages=7400-7409&amp;pmid=14612539&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="element-citation">Lee TY, Lin CT, Kuo SZUY, Chang DEK, Wu HANC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2007;<span class="ref-vol">67</span>(22):10959\xe2\x80\x9310965.</span> [<a href="/pubmed/18006841" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Peptide-mediated+targeting+to+tumor+blood+vessels+of+lung+cancer+for+drug+delivery&amp;author=TY+Lee&amp;author=CT+Lin&amp;author=SZUY+Kuo&amp;author=DEK+Chang&amp;author=HANC+Wu&amp;volume=67&amp;issue=22&amp;publication_year=2007&amp;pages=10959-10965&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="element-citation">Lee TY, Wu HANC, Tseng YUNL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2004;<span class="ref-vol">64</span>(21):8002\xe2\x80\x938008.</span> [<a href="/pubmed/15520208" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=A+novel+peptide+specifically+binding+to+nasopharyngeal+carcinoma+for+targeted+drug+delivery&amp;author=TY+Lee&amp;author=HANC+Wu&amp;author=YUNL+Tseng&amp;author=CT+Lin&amp;volume=64&amp;issue=21&amp;publication_year=2004&amp;pages=8002-8008&amp;pmid=15520208&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="element-citation">Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2002;<span class="ref-vol">62</span>(24):7190\xe2\x80\x937194.</span> [<a href="/pubmed/12499256" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Internalizing+antibodies+are+necessary+for+improved+therapeutic+efficacy+of+antibody-targeted+liposomal+drugs&amp;author=P+Sapra&amp;author=TM+Allen&amp;volume=62&amp;issue=24&amp;publication_year=2002&amp;pages=7190-7194&amp;pmid=12499256&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="element-citation">Chang D-K, Chiu C-Y, Kuo S-Y, et al.  Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. <span><span class="ref-journal"><em>Journal of Biological Chemistry</em>. </span>2009;<span class="ref-vol">284</span>(19):12905\xe2\x80\x9312916.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2676021/">PMC free article</a>]</span> [<a href="/pubmed/19276080" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Biological+Chemistry&amp;title=Antiangiogenic+targeting+liposomes+increase+therapeutic+efficacy+for+solid+tumors&amp;author=D-K+Chang&amp;author=C-Y+Chiu&amp;author=S-Y+Kuo&amp;volume=284&amp;issue=19&amp;publication_year=2009&amp;pages=12905-12916&amp;pmid=19276080&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="element-citation">Pastorino F, Paolo DD, Piccardi F, et al.  Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2008;<span class="ref-vol">14</span>(22):7320\xe2\x80\x937329.</span> [<a href="/pubmed/19010847" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Enhanced+antitumor+efficacy+of+clinical-grade+vasculature-targeted+liposomal+doxorubicin&amp;author=F+Pastorino&amp;author=DD+Paolo&amp;author=F+Piccardi&amp;volume=14&amp;issue=22&amp;publication_year=2008&amp;pages=7320-7329&amp;pmid=19010847&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="element-citation">Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2002;<span class="ref-vol">62</span>(23):6938\xe2\x80\x936943.</span> [<a href="/pubmed/12460910" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Protracted+low-dose+effects+on+human+endothelial+cell+proliferation+and+survival+in+vitro+reveal+a+selective+antiangiogenic+window+for+various+chemotherapeutic+drugs&amp;author=G+Bocci&amp;author=KC+Nicolaou&amp;author=RS+Kerbel&amp;volume=62&amp;issue=23&amp;publication_year=2002&amp;pages=6938-6943&amp;pmid=12460910&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="element-citation">Browder T, Butterfield CE, Kr&#x000e4;ling BM, et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2000;<span class="ref-vol">60</span>(7):1878\xe2\x80\x931886.</span> [<a href="/pubmed/10766175" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Antiangiogenic+scheduling+of+chemotherapy+improves+efficacy+against+experimental+drug-resistant+cancer&amp;author=T+Browder&amp;author=CE+Butterfield&amp;author=BM+Kr&#x000e4;ling&amp;volume=60&amp;issue=7&amp;publication_year=2000&amp;pages=1878-1886&amp;pmid=10766175&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="element-citation">Hanahan D, Bergers G, Bergsland E. Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. <span><span class="ref-journal"><em>The Journal of Clinical Investigation</em>. </span>2000;<span class="ref-vol">105</span>(8):1045\xe2\x80\x931047.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC300842/">PMC free article</a>]</span> [<a href="/pubmed/10772648" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+Clinical+Investigation&amp;title=Less+is,+more,+regularly:+metronomic+dosing+of+cytotoxic+drugs+can+target+tumor+angiogenesis+in+mice&amp;author=D+Hanahan&amp;author=G+Bergers&amp;author=E+Bergsland&amp;volume=105&amp;issue=8&amp;publication_year=2000&amp;pages=1045-1047&amp;pmid=10772648&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="element-citation">Klement G, Baruchel S, Rak J, et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. <span><span class="ref-journal"><em>The Journal of Clinical Investigation</em>. </span>2000;<span class="ref-vol">105</span>(8):15\xe2\x80\x9324.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC517491/">PMC free article</a>]</span> [<a href="/pubmed/10772661" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+Clinical+Investigation&amp;title=Continuous+low-dose+therapy+with+vinblastine+and+VEGF+receptor-2+antibody+induces+sustained+tumor+regression+without+overt+toxicity&amp;author=G+Klement&amp;author=S+Baruchel&amp;author=J+Rak&amp;volume=105&amp;issue=8&amp;publication_year=2000&amp;pages=15-24&amp;pmid=10619856&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="element-citation">Hurwitz H, Fehrenbacher L, Novotny W, et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. <span><span class="ref-journal"><em>The New England Journal of Medicine</em>. </span>2004;<span class="ref-vol">350</span>(23):2335\xe2\x80\x932342.</span> [<a href="/pubmed/15175435" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+New+England+Journal+of+Medicine&amp;title=Bevacizumab+plus+irinotecan,+fluorouracil,+and+leucovorin+for+metastatic+colorectal+cancer&amp;author=H+Hurwitz&amp;author=L+Fehrenbacher&amp;author=W+Novotny&amp;volume=350&amp;issue=23&amp;publication_year=2004&amp;pages=2335-2342&amp;pmid=15175435&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="element-citation">Motzer RJ, Hutson TE, Tomczak P, et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. <span><span class="ref-journal"><em>The New England Journal of Medicine</em>. </span>2007;<span class="ref-vol">356</span>(2):115\xe2\x80\x93124.</span> [<a href="/pubmed/17215529" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+New+England+Journal+of+Medicine&amp;title=Sunitinib+versus+interferon+alfa+in+metastatic+renal-cell+carcinoma&amp;author=RJ+Motzer&amp;author=TE+Hutson&amp;author=P+Tomczak&amp;volume=356&amp;issue=2&amp;publication_year=2007&amp;pages=115-124&amp;pmid=17215529&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="element-citation">Ratain MJ, Eisen TIM, Stadler WM, et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>2006;<span class="ref-vol">24</span>(16):2505\xe2\x80\x932512.</span> [<a href="/pubmed/16636341" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Phase+II+placebo-controlled+randomized+discontinuation+trial+of+sorafenib+in+patients+with+metastatic+renal+cell+carcinoma&amp;author=MJ+Ratain&amp;author=TIM+Eisen&amp;author=WM+Stadler&amp;volume=24&amp;issue=16&amp;publication_year=2006&amp;pages=2505-2512&amp;pmid=16636341&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B84">25. <span class="element-citation">Akino T, Hida K, Hida Y, et al.  Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. <span><span class="ref-journal"><em>The American Journal of Pathology</em>. </span>2009;<span class="ref-vol">175</span>(6):2657\xe2\x80\x932667.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2789618/">PMC free article</a>]</span> [<a href="/pubmed/19875502" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+American+Journal+of+Pathology&amp;title=Cytogenetic+abnormalities+of+tumor-associated+endothelial+cells+in+human+malignant+tumors&amp;author=T+Akino&amp;author=K+Hida&amp;author=Y+Hida&amp;volume=175&amp;issue=6&amp;publication_year=2009&amp;pages=2657-2667&amp;pmid=19875502&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B85">26. <span class="element-citation">Hida K, Hida Y, Amin DN, et al.  Tumor-associated endothelial cells with cytogenetic abnormalities. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2004;<span class="ref-vol">64</span>(22):8249\xe2\x80\x938255.</span> [<a href="/pubmed/15548691" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Tumor-associated+endothelial+cells+with+cytogenetic+abnormalities&amp;author=K+Hida&amp;author=Y+Hida&amp;author=DN+Amin&amp;volume=64&amp;issue=22&amp;publication_year=2004&amp;pages=8249-8255&amp;pmid=15548691&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">27. <span class="element-citation">Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. <span><span class="ref-journal"><em>The British Journal of Radiology</em>. </span>1993;<span class="ref-vol">66</span>(783):181\xe2\x80\x93196.</span> [<a href="/pubmed/7682469" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+British+Journal+of+Radiology&amp;title=Angiogenesis,+neovascular+proliferation+and+vascular+pathophysiology+as+targets+for+cancer+therapy&amp;author=J+Denekamp&amp;volume=66&amp;issue=783&amp;publication_year=1993&amp;pages=181-196&amp;pmid=7682469&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26">28. <span class="element-citation">Wu HANC, Li PIC. Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. <span><span class="ref-journal"><em>Journal of Cancer Molecules</em>. </span>2008;<span class="ref-vol">4</span>(1):17\xe2\x80\x9322.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Cancer+Molecules&amp;title=Proteins+expressed+on+tumor+endothelial+cells+as+potential+targets+for+anti-angiogenic+therapy&amp;author=HANC+Wu&amp;author=PIC+Li&amp;volume=4&amp;issue=1&amp;publication_year=2008&amp;pages=17-22&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27">29. <span class="element-citation">Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. <span><span class="ref-journal"><em>Science</em>. </span>2005;<span class="ref-vol">307</span>(5706):58\xe2\x80\x9362.</span> [<a href="/pubmed/15637262" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Normalization+of+tumor+vasculature:+an+emerging+concept+in+antiangiogenic+therapy&amp;author=RK+Jain&amp;volume=307&amp;issue=5706&amp;publication_year=2005&amp;pages=58-62&amp;pmid=15637262&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28">30. <span class="element-citation">Pietras K, Rubin K, Sjoblom T, et al.  Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2002;<span class="ref-vol">62</span>(19):5476\xe2\x80\x935484.</span> [<a href="/pubmed/12359756" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Inhibition+of+PDGF+receptor+signaling+in+tumor+stroma+enhances+antitumor+effect+of+chemotherapy&amp;author=K+Pietras&amp;author=K+Rubin&amp;author=T+Sjoblom&amp;volume=62&amp;issue=19&amp;publication_year=2002&amp;pages=5476-5484&amp;pmid=12359756&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29">31. <span class="element-citation">Wildiers H, Guetens G, De Boeck G, et al.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. <span><span class="ref-journal"><em>British Journal of Cancer</em>. </span>2003;<span class="ref-vol">88</span>(12):1979\xe2\x80\x931986.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2741115/">PMC free article</a>]</span> [<a href="/pubmed/12799646" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+Journal+of+Cancer&amp;title=Effect+of+antivascular+endothelial+growth+factor+treatment+on+the+intratumoral+uptake+of+CPT-11&amp;author=H+Wildiers&amp;author=G+Guetens&amp;author=G+De+Boeck&amp;volume=88&amp;issue=12&amp;publication_year=2003&amp;pages=1979-1986&amp;pmid=12799646&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30">32. <span class="element-citation">Willett CG, Boucher Y, di Tomaso E, et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>2004;<span class="ref-vol">10</span>(2):145\xe2\x80\x93147.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2693485/">PMC free article</a>]</span> [<a href="/pubmed/14745444" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=Direct+evidence+that+the+VEGF-specific+antibody+bevacizumab+has+antivascular+effects+in+human+rectal+cancer&amp;author=CG+Willett&amp;author=Y+Boucher&amp;author=E+di+Tomaso&amp;volume=10&amp;issue=2&amp;publication_year=2004&amp;pages=145-147&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31">33. <span class="element-citation">Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. <span><span class="ref-journal"><em>Oncology</em>. </span>2005;<span class="ref-vol">19</span>(4, supplement 3):7\xe2\x80\x9316.</span> [<a href="/pubmed/15934498" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncology&amp;title=Antiangiogenic+therapy+for+cancer:+current+and+emerging+concepts&amp;author=RK+Jain&amp;volume=19&amp;issue=4,+supplement+3&amp;publication_year=2005&amp;pages=7-16&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32">34. <span class="element-citation">Arap W, Kolonin MG, Trepel M, et al.  Steps toward mapping the human vasculature by phage display. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>2002;<span class="ref-vol">8</span>(2):121\xe2\x80\x93127.</span> [<a href="/pubmed/11821895" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=Steps+toward+mapping+the+human+vasculature+by+phage+display&amp;author=W+Arap&amp;author=MG+Kolonin&amp;author=M+Trepel&amp;volume=8&amp;issue=2&amp;publication_year=2002&amp;pages=121-127&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33">35. <span class="element-citation">Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. <span><span class="ref-journal"><em>European Journal of Cancer</em>. </span>2007;<span class="ref-vol">43</span>(8):1242\xe2\x80\x931250.</span> [<a href="/pubmed/17449238" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+Journal+of+Cancer&amp;title=Novel+challenges+in+exploring+peptide+ligands+and+corresponding+tissue-specific+endothelial+receptors&amp;author=ML+Balestrieri&amp;author=C+Napoli&amp;volume=43&amp;issue=8&amp;publication_year=2007&amp;pages=1242-1250&amp;pmid=17449238&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34">36. <span class="element-citation">Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. <span><span class="ref-journal"><em>Science</em>. </span>1998;<span class="ref-vol">279</span>(5349):377\xe2\x80\x93380.</span> [<a href="/pubmed/9430587" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cancer+treatment+by+targeted+drug+delivery+to+tumor+vasculature+in+a+mouse+model&amp;author=W+Arap&amp;author=R+Pasqualini&amp;author=E+Ruoslahti&amp;volume=279&amp;issue=5349&amp;publication_year=1998&amp;pages=377-380&amp;pmid=9430587&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35">37. <span class="element-citation">Pasqualini R, Koivunen E, Kain R, et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2000;<span class="ref-vol">60</span>(3):722\xe2\x80\x93727.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4469333/">PMC free article</a>]</span> [<a href="/pubmed/10676659" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Aminopeptidase+N+is+a+receptor+for+tumor-homing+peptides+and+a+target+for+inhibiting+angiogenesis&amp;author=R+Pasqualini&amp;author=E+Koivunen&amp;author=R+Kain&amp;volume=60&amp;issue=3&amp;publication_year=2000&amp;pages=722-727&amp;pmid=10676659&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36">38. <span class="element-citation">Wu HC, Huang YL, Chao TT, et al.  Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. <span><span class="ref-journal"><em>Journal of Clinical Microbiology</em>. </span>2001;<span class="ref-vol">39</span>(3):977\xe2\x80\x93982.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC87860/">PMC free article</a>]</span> [<a href="/pubmed/11230414" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Microbiology&amp;title=Identification+of+B-cell+epitope+of+dengue+virus+type+1+and+its+application+in+diagnosis+of+patients&amp;author=HC+Wu&amp;author=YL+Huang&amp;author=TT+Chao&amp;volume=39&amp;issue=3&amp;publication_year=2001&amp;pages=977-982&amp;pmid=11230414&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37">39. <span class="element-citation">Wu HANC, Jung MEIY, Chiu CY, et al.  Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. <span><span class="ref-journal"><em>The Journal of General Virology</em>. </span>2003;<span class="ref-vol">84</span>(10):2771\xe2\x80\x932779.</span> [<a href="/pubmed/13679612" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+General+Virology&amp;title=Identification+of+a+dengue+virus+type+2+(DEN-2)+serotype-specific+B-cell+epitope+and+detection+of+DEN-2-immunized+animal+serum+samples+using+an+epitope-based+peptide+antigen&amp;author=HANC+Wu&amp;author=MEIY+Jung&amp;author=CY+Chiu&amp;volume=84&amp;issue=10&amp;publication_year=2003&amp;pages=2771-2779&amp;pmid=13679612&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38">40. <span class="element-citation">Chen YUNC, Huang HN, Lin CT, Chen YIF, King CC, Wu HANC. Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. <span><span class="ref-journal"><em>Clinical and Vaccine Immunology</em>. </span>2007;<span class="ref-vol">14</span>(4):404\xe2\x80\x93411.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1865613/">PMC free article</a>]</span> [<a href="/pubmed/17287314" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+and+Vaccine+Immunology&amp;title=Generation+and+characterization+of+monoclonal+antibodies+against+dengue+virus+type+1+for+epitope+mapping+and+serological+detection+by+epitope-based+peptide+antigens&amp;author=YUNC+Chen&amp;author=HN+Huang&amp;author=CT+Lin&amp;author=YIF+Chen&amp;author=CC+King&amp;volume=14&amp;issue=4&amp;publication_year=2007&amp;pages=404-411&amp;pmid=17287314&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39">41. <span class="element-citation">Atwell S, Ultsch M, De Vos AM, Wells JA. Structural plasticity in a remodeled protein-protein interface. <span><span class="ref-journal"><em>Science</em>. </span>1997;<span class="ref-vol">278</span>(5340):1125\xe2\x80\x931128.</span> [<a href="/pubmed/9353194" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Structural+plasticity+in+a+remodeled+protein-protein+interface&amp;author=S+Atwell&amp;author=M+Ultsch&amp;author=AM+De+Vos&amp;author=JA+Wells&amp;volume=278&amp;issue=5340&amp;publication_year=1997&amp;pages=1125-1128&amp;pmid=9353194&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40">42. <span class="element-citation">Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhl&#x000e9;n M, Nygren PERA. Binding proteins selected from combinatorial libraries of an <em>&#x003b1;</em>-helical bacterial receptor domain. <span><span class="ref-journal"><em>Nature Biotechnology</em>. </span>1997;<span class="ref-vol">15</span>(8):772\xe2\x80\x93777.</span> [<a href="/pubmed/9255793" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Biotechnology&amp;title=Binding+proteins+selected+from+combinatorial+libraries+of+an+&#x003b1;-helical+bacterial+receptor+domain&amp;author=K+Nord&amp;author=E+Gunneriusson&amp;author=J+Ringdahl&amp;author=S+Stahl&amp;author=M+Uhl&#x000e9;n&amp;volume=15&amp;issue=8&amp;publication_year=1997&amp;pages=772-777&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B41">43. <span class="element-citation">Li B, Tom JYK, Oare D, et al.  Minimization of a polypeptide hormone. <span><span class="ref-journal"><em>Science</em>. </span>1995;<span class="ref-vol">270</span>(5242):1657\xe2\x80\x931660.</span> [<a href="/pubmed/7502074" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Minimization+of+a+polypeptide+hormone&amp;author=B+Li&amp;author=JYK+Tom&amp;author=D+Oare&amp;volume=270&amp;issue=5242&amp;publication_year=1995&amp;pages=1657-1660&amp;pmid=7502074&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B42">44. <span class="element-citation">Sugahara KN, Teesalu T, Karmali PP, et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. <span><span class="ref-journal"><em>Cancer Cell</em>. </span>2009;<span class="ref-vol">16</span>(6):510\xe2\x80\x93520.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2791543/">PMC free article</a>]</span> [<a href="/pubmed/19962669" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Tissue-penetrating+delivery+of+compounds+and+nanoparticles+into+tumors&amp;author=KN+Sugahara&amp;author=T+Teesalu&amp;author=PP+Karmali&amp;volume=16&amp;issue=6&amp;publication_year=2009&amp;pages=510-520&amp;pmid=19962669&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B43">45. <span class="element-citation">Castano AR, Tangri S, Miller JEW, et al.  Peptide binding and presentation by mouse CD1. <span><span class="ref-journal"><em>Science</em>. </span>1995;<span class="ref-vol">269</span>(5221):223\xe2\x80\x93226.</span> [<a href="/pubmed/7542403" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Peptide+binding+and+presentation+by+mouse+CD1&amp;author=AR+Castano&amp;author=S+Tangri&amp;author=JEW+Miller&amp;volume=269&amp;issue=5221&amp;publication_year=1995&amp;pages=223-226&amp;pmid=7542403&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B44">46. <span class="element-citation">Mai J, Song S, Rui M, et al.  A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. <span><span class="ref-journal"><em>Journal of Controlled Release</em>. </span>2009;<span class="ref-vol">139</span>(3):174\xe2\x80\x93181.</span> [<a href="/pubmed/19576253" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Controlled+Release&amp;title=A+synthetic+peptide+mediated+active+targeting+of+cisplatin+liposomes+to+Tie2+expressing+cells&amp;author=J+Mai&amp;author=S+Song&amp;author=M+Rui&amp;volume=139&amp;issue=3&amp;publication_year=2009&amp;pages=174-181&amp;pmid=19576253&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B45">47. <span class="element-citation">Folgori A, Tafi R, Meola A, et al.  A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. <span><span class="ref-journal"><em>EMBO Journal</em>. </span>1994;<span class="ref-vol">13</span>(9):2236\xe2\x80\x932243.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC395079/">PMC free article</a>]</span> [<a href="/pubmed/7514533" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+Journal&amp;title=A+general+strategy+to+identify+mimotopes+of+pathological+antigens+using+only+random+peptide+libraries+and+human+sera&amp;author=A+Folgori&amp;author=R+Tafi&amp;author=A+Meola&amp;volume=13&amp;issue=9&amp;publication_year=1994&amp;pages=2236-2243&amp;pmid=7514533&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B46">48. <span class="element-citation">Liu IJ, Hsueh POR, Lin CT, et al.  Disease-specific B cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. <span><span class="ref-journal"><em>The Journal of Infectious Diseases</em>. </span>2004;<span class="ref-vol">190</span>(4):797\xe2\x80\x93809.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7109815/">PMC free article</a>]</span> [<a href="/pubmed/15272409" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+Infectious+Diseases&amp;title=Disease-specific+B+cell+epitopes+for+serum+antibodies+from+patients+with+severe+acute+respiratory+syndrome+(SARS)+and+serologic+detection+of+SARS+antibodies+by+epitope-based+peptide+antigens&amp;author=IJ+Liu&amp;author=POR+Hsueh&amp;author=CT+Lin&amp;volume=190&amp;issue=4&amp;publication_year=2004&amp;pages=797-809&amp;pmid=15272409&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B47">49. <span class="element-citation">Mazzucchelli L, Burritt JB, Jesaitis AJ, et al.  Cell-specific peptide binding by human neutrophils. <span><span class="ref-journal"><em>Blood</em>. </span>1999;<span class="ref-vol">93</span>(5):1738\xe2\x80\x931748.</span> [<a href="/pubmed/10029604" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Cell-specific+peptide+binding+by+human+neutrophils&amp;author=L+Mazzucchelli&amp;author=JB+Burritt&amp;author=AJ+Jesaitis&amp;volume=93&amp;issue=5&amp;publication_year=1999&amp;pages=1738-1748&amp;pmid=10029604&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B66">50. <span class="element-citation">Lo A, Lin CT, Wu HANC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. <span><span class="ref-journal"><em>Molecular Cancer Therapeutics</em>. </span>2008;<span class="ref-vol">7</span>(3):579\xe2\x80\x93589.</span> [<a href="/pubmed/18347144" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Molecular+Cancer+Therapeutics&amp;title=Hepatocellular+carcinoma+cell-specific+peptide+ligand+for+targeted+drug+delivery&amp;author=A+Lo&amp;author=CT+Lin&amp;author=HANC+Wu&amp;volume=7&amp;issue=3&amp;publication_year=2008&amp;pages=579-589&amp;pmid=18347144&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B80">51. <span class="element-citation">Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. <span><span class="ref-journal"><em>Analytical Biochemistry</em>. </span>1966;<span class="ref-vol">14</span>(3):328\xe2\x80\x93336.</span> [<a href="/pubmed/4161471" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Analytical+Biochemistry&amp;title=Determination+of+free+amino+groups+in+proteins+by+trinitrobenzenesulfonic+acid&amp;author=AFSA+Habeeb&amp;volume=14&amp;issue=3&amp;publication_year=1966&amp;pages=328-336&amp;pmid=4161471&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B81">52. <span class="element-citation">Zalipsky S, Mullah N, Harding JA, Gittelman J, Guo L, DeFrees SA. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. <span><span class="ref-journal"><em>Bioconjugate Chemistry</em>. </span>1997;<span class="ref-vol">8</span>(2):111\xe2\x80\x93118.</span> [<a href="/pubmed/9095350" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioconjugate+Chemistry&amp;title=Poly(ethylene+glycol)-grafted+liposomes+with+oligopeptide+or+oligosaccharide+ligands+appended+to+the+termini+of+the+polymer+chains&amp;author=S+Zalipsky&amp;author=N+Mullah&amp;author=JA+Harding&amp;author=J+Gittelman&amp;author=L+Guo&amp;volume=8&amp;issue=2&amp;publication_year=1997&amp;pages=111-118&amp;pmid=9095350&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B82">53. <span class="element-citation">Kirpotin D, Park JW, Hong K, et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. <span><span class="ref-journal"><em>Biochemistry</em>. </span>1997;<span class="ref-vol">36</span>(1):66\xe2\x80\x9375.</span> [<a href="/pubmed/8993319" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Sterically+stabilized+anti-HER2+immunoliposomes:+design+and+targeting+to+human+breast+cancer+cells+in+vitro&amp;author=D+Kirpotin&amp;author=JW+Park&amp;author=K+Hong&amp;volume=36&amp;issue=1&amp;publication_year=1997&amp;pages=66-75&amp;pmid=8993319&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B83">54. <span class="element-citation">Curnis F, Arrigoni G, Sacchi A, et al.  Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2002;<span class="ref-vol">62</span>(3):867\xe2\x80\x93874.</span> [<a href="/pubmed/11830545" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Differential+binding+of+drugs+containing+the+NGR+motif+to+CD13+isoforms+in+tumor+vessels,+epithelia,+and+myeloid+cells&amp;author=F+Curnis&amp;author=G+Arrigoni&amp;author=A+Sacchi&amp;volume=62&amp;issue=3&amp;publication_year=2002&amp;pages=867-874&amp;pmid=11830545&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B48">55. <span class="element-citation">Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. <span><span class="ref-journal"><em>Advanced Drug Delivery Reviews</em>. </span>2004;<span class="ref-vol">56</span>(11):1649\xe2\x80\x931659.</span> [<a href="/pubmed/15350294" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Advanced+Drug+Delivery+Reviews&amp;title=Nanoparticle+and+targeted+systems+for+cancer+therapy&amp;author=L+Brannon-Peppas&amp;author=JO+Blanchette&amp;volume=56&amp;issue=11&amp;publication_year=2004&amp;pages=1649-1659&amp;pmid=15350294&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B49">56. <span class="element-citation">Duncan R. Polymer conjugates as anticancer nanomedicines. <span><span class="ref-journal"><em>Nature Reviews Cancer</em>. </span>2006;<span class="ref-vol">6</span>(9):688\xe2\x80\x93701.</span> [<a href="/pubmed/16900224" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Reviews+Cancer&amp;title=Polymer+conjugates+as+anticancer+nanomedicines&amp;author=R+Duncan&amp;volume=6&amp;issue=9&amp;publication_year=2006&amp;pages=688-701&amp;pmid=16900224&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B50">57. <span class="element-citation">Muggia F, Hamilton A. Phase III data on Caelyx in ovarian cancer. <span><span class="ref-journal"><em>European Journal of Cancer</em>. </span>2001;<span class="ref-vol">37</span>(supplement 9):15\xe2\x80\x9318.</span> [<a href="/pubmed/11741769" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+Journal+of+Cancer&amp;title=Phase+III+data+on+Caelyx+in+ovarian+cancer&amp;author=F+Muggia&amp;author=A+Hamilton&amp;volume=37&amp;issue=supplement+9&amp;publication_year=2001&amp;pages=15-18&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B51">58. <span class="element-citation">Papahadjopoulos D, Allen TM, Gabizon A, et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. <span><span class="ref-journal"><em>Proceedings of the National Academy of Sciences of the United States of America</em>. </span>1991;<span class="ref-vol">88</span>(24):11460\xe2\x80\x9311464.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC53155/">PMC free article</a>]</span> [<a href="/pubmed/1763060" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=Sterically+stabilized+liposomes:+improvements+in+pharmacokinetics+and+antitumor+therapeutic+efficacy&amp;author=D+Papahadjopoulos&amp;author=TM+Allen&amp;author=A+Gabizon&amp;volume=88&amp;issue=24&amp;publication_year=1991&amp;pages=11460-11464&amp;pmid=1763060&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B52">59. <span class="element-citation">Colbern GT, Hiller AJ, Musterer RS, Pegg E, Henderson IC, Working PK. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. <span><span class="ref-journal"><em>Journal of Liposome Research</em>. </span>1999;<span class="ref-vol">9</span>(4):523\xe2\x80\x93538.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Liposome+Research&amp;title=Significant+increase+in+antitumor+potency+of+doxorubicin+HCl+by+its+encapsulation+in+pegylated+liposomes&amp;author=GT+Colbern&amp;author=AJ+Hiller&amp;author=RS+Musterer&amp;author=E+Pegg&amp;author=IC+Henderson&amp;volume=9&amp;issue=4&amp;publication_year=1999&amp;pages=523-538&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B53">60. <span class="element-citation">Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. <span><span class="ref-journal"><em>Journal of Controlled Release</em>. </span>2010;<span class="ref-vol">142</span>(2):167\xe2\x80\x93173.</span> [<a href="/pubmed/19861140" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Controlled+Release&amp;title=Sequential+administration+with+oxaliplatin-containing+PEG-coated+cationic+liposomes+promotes+a+significant+delivery+of+subsequent+dose+into+murine+solid+tumor&amp;author=AS+Abu+Lila&amp;author=Y+Doi&amp;author=K+Nakamura&amp;author=T+Ishida&amp;author=H+Kiwada&amp;volume=142&amp;issue=2&amp;publication_year=2010&amp;pages=167-173&amp;pmid=19861140&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B54">61. <span class="element-citation">Orlowski RZ, Nagler A, Sonneveld P, et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>2007;<span class="ref-vol">25</span>(25):3892\xe2\x80\x933901.</span> [<a href="/pubmed/17679727" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Randomized+phase+III+study+of+pegylated+liposomal+doxorubicin+plus+bortezomib+compared+with+bortezomib+alone+in+relapsed+or+refractory+multiple+myeloma:+combination+therapy+improves+time+to+progression&amp;author=RZ+Orlowski&amp;author=A+Nagler&amp;author=P+Sonneveld&amp;volume=25&amp;issue=25&amp;publication_year=2007&amp;pages=3892-3901&amp;pmid=17679727&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B55">62. <span class="element-citation">Safra T, Muggia F, Jeffers S, et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500&#x02009;mg/m<sup>2</sup>\n. <span><span class="ref-journal"><em>Annals of Oncology</em>. </span>2000;<span class="ref-vol">11</span>(8):1029\xe2\x80\x931033.</span> [<a href="/pubmed/11038041" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+Oncology&amp;title=Pegylated+liposomal+doxorubicin+(doxil):+reduced+clinical+cardiotoxicity+in+patients+reaching+or+exceeding+cumulative+doses+of+500&#x02009;mg/m2&#10;&amp;author=T+Safra&amp;author=F+Muggia&amp;author=S+Jeffers&amp;volume=11&amp;issue=8&amp;publication_year=2000&amp;pages=1029-1033&amp;pmid=11038041&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B56">63. <span class="element-citation">Harrington KJ, Mohammadtaghi S, Uster PS, et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2001;<span class="ref-vol">7</span>(2):243\xe2\x80\x93254.</span> [<a href="/pubmed/11234875" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Effective+targeting+of+solid+tumors+in+patients+with+locally+advanced+cancers+by+radiolabeled+pegylated+liposomes&amp;author=KJ+Harrington&amp;author=S+Mohammadtaghi&amp;author=PS+Uster&amp;volume=7&amp;issue=2&amp;publication_year=2001&amp;pages=243-254&amp;pmid=11234875&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B57">64. <span class="element-citation">Marina NM, Cochrane D, Harney E, et al.  Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2002;<span class="ref-vol">8</span>(2):413\xe2\x80\x93418.</span> [<a href="/pubmed/11839657" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Dose+escalation+and+pharmacokinetics+of+pegylated+liposomal+doxorubicin+(Doxil)+in+children+with+solid+tumors:+a+pediatric+oncology+group+study&amp;author=NM+Marina&amp;author=D+Cochrane&amp;author=E+Harney&amp;volume=8&amp;issue=2&amp;publication_year=2002&amp;pages=413-418&amp;pmid=11839657&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B58">65. <span class="element-citation">Batist G. Cardiac safety of liposomal anthracyclines. <span><span class="ref-journal"><em>Cardiovascular Toxicology</em>. </span>2007;<span class="ref-vol">7</span>(2):72\xe2\x80\x9374.</span> [<a href="/pubmed/17652807" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovascular+Toxicology&amp;title=Cardiac+safety+of+liposomal+anthracyclines&amp;author=G+Batist&amp;volume=7&amp;issue=2&amp;publication_year=2007&amp;pages=72-74&amp;pmid=17652807&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B70">66. <span class="element-citation">Hashizume H, Baluk P, Morikawa S, et al.  Openings between defective endothelial cells explain tumor vessel leakiness. <span><span class="ref-journal"><em>American Journal of Pathology</em>. </span>2000;<span class="ref-vol">156</span>(4):1363\xe2\x80\x931380.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1876882/">PMC free article</a>]</span> [<a href="/pubmed/10751361" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=American+Journal+of+Pathology&amp;title=Openings+between+defective+endothelial+cells+explain+tumor+vessel+leakiness&amp;author=H+Hashizume&amp;author=P+Baluk&amp;author=S+Morikawa&amp;volume=156&amp;issue=4&amp;publication_year=2000&amp;pages=1363-1380&amp;pmid=10751361&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B71">67. <span class="element-citation">Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. <span><span class="ref-journal"><em>Pharmacological Reviews</em>. </span>1999;<span class="ref-vol">51</span>(4):691\xe2\x80\x93743.</span> [<a href="/pubmed/10581328" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacological+Reviews&amp;title=Optimizing+liposomes+for+delivery+of+chemotherapeutic+agents+to+solid+tumors&amp;author=DC+Drummond&amp;author=O+Meyer&amp;author=K+Hong&amp;author=DB+Kirpotin&amp;author=D+Papahadjopoulos&amp;volume=51&amp;issue=4&amp;publication_year=1999&amp;pages=691-743&amp;pmid=10581328&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B72">68. <span class="element-citation">Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. <span><span class="ref-journal"><em>Cancer Research</em>. </span>1986;<span class="ref-vol">46</span>(12):6387\xe2\x80\x936392.</span> [<a href="/pubmed/2946403" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=A+new+concept+for+macromolecular+therapeutics+in+cancer+chemotherapy:+mechanism+of+tumoritropic+accumulation+of+proteins+and+the+antitumor+agent+smancs&amp;author=Y+Matsumura&amp;author=H+Maeda&amp;volume=46&amp;issue=12&amp;publication_year=1986&amp;pages=6387-6392&amp;pmid=2946403&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B73">69. <span class="element-citation">Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. <span><span class="ref-journal"><em>Journal of Controlled Release</em>. </span>2000;<span class="ref-vol">65</span>(1-2):271\xe2\x80\x93284.</span> [<a href="/pubmed/10699287" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Controlled+Release&amp;title=Tumor+vascular+permeability+and+the+EPR+effect+in+macromolecular+therapeutics:+a+review&amp;author=H+Maeda&amp;author=J+Wu&amp;author=T+Sawa&amp;author=Y+Matsumura&amp;author=K+Hori&amp;volume=65&amp;issue=1-2&amp;publication_year=2000&amp;pages=271-284&amp;pmid=10699287&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B74">70. <span class="element-citation">Northfelt DW, Martin FJ, Working P, et al.  Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi&#x02019;s sarcoma. <span><span class="ref-journal"><em>Journal of Clinical Pharmacology</em>. </span>1996;<span class="ref-vol">36</span>(1):55\xe2\x80\x9363.</span> [<a href="/pubmed/8932544" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Pharmacology&amp;title=Doxorubicin+encapsulated+in+liposomes+containing+surface-bound+polyethylene+glycol:+pharmacokinetics,+tumor+localization,+and+safety+in+patients+with+AIDS-related+Kaposi&#x02019;s+sarcoma&amp;author=DW+Northfelt&amp;author=FJ+Martin&amp;author=P+Working&amp;volume=36&amp;issue=1&amp;publication_year=1996&amp;pages=55-63&amp;pmid=8932544&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B59">71. <span class="element-citation">Uziely B, Jeffers S, Isacson R, et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>1995;<span class="ref-vol">13</span>(7):1777\xe2\x80\x931785.</span> [<a href="/pubmed/7602367" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Liposomal+doxorubicin:+antitumor+activity+and+unique+toxicities+during+two+complementary+phase+I+studies&amp;author=B+Uziely&amp;author=S+Jeffers&amp;author=R+Isacson&amp;volume=13&amp;issue=7&amp;publication_year=1995&amp;pages=1777-1785&amp;pmid=7602367&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B60">72. <span class="element-citation">Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. <span><span class="ref-journal"><em>Cancer</em>. </span>1995;<span class="ref-vol">75</span>(8):2169\xe2\x80\x932173.</span> [<a href="/pubmed/7697608" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Hand-foot+syndrome+associated+with+liposome-encapsulated+doxorubicin+therapy&amp;author=KB+Gordon&amp;author=A+Tajuddin&amp;author=J+Guitart&amp;author=TM+Kuzel&amp;author=LR+Eramo&amp;volume=75&amp;issue=8&amp;publication_year=1995&amp;pages=2169-2173&amp;pmid=7697608&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B61">73. <span class="element-citation">Matsumura Y, Gotoh M, Muro K, et al.  Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. <span><span class="ref-journal"><em>Annals of Oncology</em>. </span>2004;<span class="ref-vol">15</span>(3):517\xe2\x80\x93525.</span> [<a href="/pubmed/14998859" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+Oncology&amp;title=Phase+I+and+pharmacokinetic+study+of+MCC-465,+a+doxorubicin+(DXR)+encapsulated+in+PEG+immunoliposome,+in+patients+with+metastatic+stomach+cancer&amp;author=Y+Matsumura&amp;author=M+Gotoh&amp;author=K+Muro&amp;volume=15&amp;issue=3&amp;publication_year=2004&amp;pages=517-525&amp;pmid=14998859&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B62">74. <span class="element-citation">Al-Batran SE, Bischoff J, Von Minckwitz G, et al.  The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. <span><span class="ref-journal"><em>British Journal of Cancer</em>. </span>2006;<span class="ref-vol">94</span>(11):1615\xe2\x80\x931620.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2361305/">PMC free article</a>]</span> [<a href="/pubmed/16685267" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+Journal+of+Cancer&amp;title=The+clinical+benefit+of+pegylated+liposomal+doxorubicin+in+patients+with+metastatic+breast+cancer+previously+treated+with+conventional+anthracyclines:+a+multicentre+phase+II+trial&amp;author=SE+Al-Batran&amp;author=J+Bischoff&amp;author=G+Von+Minckwitz&amp;volume=94&amp;issue=11&amp;publication_year=2006&amp;pages=1615-1620&amp;pmid=16685267&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B63">75. <span class="element-citation">Pastorino F, Brignole C, Paolo D, et al.  Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2006;<span class="ref-vol">66</span>(20):10073\xe2\x80\x9310082.</span> [<a href="/pubmed/17047071" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Targeting+liposomal+chemotherapy+via+both+tumor+cell-specific+and+tumor+vasculature-specific+ligands+potentiates+therapeutic+efficacy&amp;author=F+Pastorino&amp;author=C+Brignole&amp;author=D+Paolo&amp;volume=66&amp;issue=20&amp;publication_year=2006&amp;pages=10073-10082&amp;pmid=17047071&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B64">76. <span class="element-citation">Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML. Penetration of tumor tissue by antibodies and other immunoproteins. <span><span class="ref-journal"><em>Annals of the New York Academy of Sciences</em>. </span>1991;<span class="ref-vol">618</span>:367\xe2\x80\x93382.</span> [<a href="/pubmed/2006796" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+the+New+York+Academy+of+Sciences&amp;title=Penetration+of+tumor+tissue+by+antibodies+and+other+immunoproteins&amp;author=TR+Shockley&amp;author=K+Lin&amp;author=JA+Nagy&amp;author=RG+Tompkins&amp;author=HF+Dvorak&amp;volume=618&amp;publication_year=1991&amp;pages=367-382&amp;pmid=2006796&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B65">77. <span class="element-citation">Adams GP, Schier R, McCall AM, et al.  High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2001;<span class="ref-vol">61</span>(12):4750\xe2\x80\x934755.</span> [<a href="/pubmed/11406547" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=High+affinity+restricts+the+localization+and+tumor+penetration+of+single-chain+Fv+antibody+molecules&amp;author=GP+Adams&amp;author=R+Schier&amp;author=AM+McCall&amp;volume=61&amp;issue=12&amp;publication_year=2001&amp;pages=4750-4755&amp;pmid=11406547&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B67">78. <span class="element-citation">Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. <span><span class="ref-journal"><em>Current Pharmaceutical Design</em>. </span>2004;<span class="ref-vol">10</span>(19):2335\xe2\x80\x932343.</span> [<a href="/pubmed/15279612" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Current+Pharmaceutical+Design&amp;title=Cancer-specific+ligands+identified+from+screening+of+peptide-display+libraries&amp;author=T+Mori&amp;volume=10&amp;issue=19&amp;publication_year=2004&amp;pages=2335-2343&amp;pmid=15279612&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B68">79. <span class="element-citation">Bolotin EM, Cohen R, Bar LK, et al.  Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. <span><span class="ref-journal"><em>Journal of Liposome Research</em>. </span>1994;<span class="ref-vol">4</span>(1):455\xe2\x80\x93479.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Liposome+Research&amp;title=Ammonium+sulfate+gradients+for+efficient+and+stable+remote+loading+of+amphipathic+weak+bases+into+liposomes+and+ligandoliposomes&amp;author=EM+Bolotin&amp;author=R+Cohen&amp;author=LK+Bar&amp;volume=4&amp;issue=1&amp;publication_year=1994&amp;pages=455-479&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B69">80. <span class="element-citation">Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. <span><span class="ref-journal"><em>Cancer Research</em>. </span>1994;<span class="ref-vol">54</span>(11):2830\xe2\x80\x932833.</span> [<a href="/pubmed/8187061" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Liposomal+vincristine+which+exhibits+increased+drug+retention+and+increased+circulation+longevity+cures+mice+bearing+P388+tumors&amp;author=NL+Boman&amp;author=D+Masin&amp;author=LD+Mayer&amp;author=PR+Cullis&amp;author=MB+Bally&amp;volume=54&amp;issue=11&amp;publication_year=1994&amp;pages=2830-2833&amp;pmid=8187061&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B75">81. <span class="element-citation">Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. <span><span class="ref-journal"><em>Clinical Pharmacokinetics</em>. </span>2003;<span class="ref-vol">42</span>(5):419\xe2\x80\x93436.</span> [<a href="/pubmed/12739982" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Pharmacokinetics&amp;title=Pharmacokinetics+of+pegylated+liposomal+doxorubicin:+review+of+animal+and+human+studies&amp;author=A+Gabizon&amp;author=H+Shmeeda&amp;author=Y+Barenholz&amp;volume=42&amp;issue=5&amp;publication_year=2003&amp;pages=419-436&amp;pmid=12739982&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B76">82. <span class="element-citation">Vingerhoeds MH, Steerenberg PA, Hendriks JJGW, et al.  Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. <span><span class="ref-journal"><em>British Journal of Cancer</em>. </span>1996;<span class="ref-vol">74</span>(7):1023\xe2\x80\x931029.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2077130/">PMC free article</a>]</span> [<a href="/pubmed/8855969" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+Journal+of+Cancer&amp;title=Immunoliposome-mediated+targeting+of+doxorubicin+to+human+ovarian+carcinoma+in+vitro+and+in+vivo&amp;author=MH+Vingerhoeds&amp;author=PA+Steerenberg&amp;author=JJGW+Hendriks&amp;volume=74&amp;issue=7&amp;publication_year=1996&amp;pages=1023-1029&amp;pmid=8855969&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B77">83. <span class="element-citation">Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2000;<span class="ref-vol">6</span>(5):1949\xe2\x80\x931957.</span> [<a href="/pubmed/10815920" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Nuclear+delivery+of+doxorubicin+via+folate-targeted+liposomes+with+bypass+of+multidrug-resistance+efflux+pump&amp;author=D+Goren&amp;author=AT+Horowitz&amp;author=D+Tzemach&amp;author=M+Tarshish&amp;author=S+Zalipsky&amp;volume=6&amp;issue=5&amp;publication_year=2000&amp;pages=1949-1957&amp;pmid=10815920&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B78">84. <span class="element-citation">Sugano M, Egilmez NK, Yokota SJ, et al.  Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2000;<span class="ref-vol">60</span>(24):6942\xe2\x80\x936949.</span> [<a href="/pubmed/11156394" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Antibody+targeting+of+doxorubicin-loaded+liposomes+suppresses+the+growth+and+metastatic+spread+of+established+human+lung+tumor+xenografts+in+severe+combined+immunodeficient+mice&amp;author=M+Sugano&amp;author=NK+Egilmez&amp;author=SJ+Yokota&amp;volume=60&amp;issue=24&amp;publication_year=2000&amp;pages=6942-6949&amp;pmid=11156394&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B79">85. <span class="element-citation">Park JW, Hong K, Kirpotin DB, et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2002;<span class="ref-vol">8</span>(4):1172\xe2\x80\x931181.</span> [<a href="/pubmed/11948130" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Anti-HER2+immunoliposomes:+enhanced+efficacy+attributable+to+targeted+delivery&amp;author=JW+Park&amp;author=K+Hong&amp;author=DB+Kirpotin&amp;volume=8&amp;issue=4&amp;publication_year=2002&amp;pages=1172-1181&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2864512&amp;issue-id=180269&amp;journal-id=859&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">Journal of Oncology</span> are provided here courtesy of <strong>Hindawi Limited</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2864512/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2864512/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2864512/pdf/JO2010-723798.pdf">PDF (2.5M)</a></li> | <li><a href="#" data-citationid="PMC2864512" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2864512%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2864512%2F&amp;text=Peptide-Mediated%20Liposomal%20Drug%20Delivery%20System%20Targeting%20Tumor%20Blood%20Vessels%20in%20Anticancer%20Therapy"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2864512%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="20454584" data-aiid="2864512" data-aid="2864512" data-iid="180269" data-domainid="859" data-domain="jonc" data-accid="PMC2864512" data-md5="9ff96c3db35df646c17b0068019d1dbe"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:38:14-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B572CE9A363910000000008DF08DD&amp;ncbi_session=8A1B572CE9A4BF51_2271SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2864512%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=jonc&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2864512/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B572CE9A4BF51_2271SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'